- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Emergent BioSolutions Reveals New Financial Plan
Strategy includes a layoff of nearly 400 employees.
With the goal of strengthening its core business and financial position, Emergent BioSolutions has announced it is de-emphasizing focus on growth in its contract development and manufacturing (CDMO) services business. Additionally, the organization will be reducing operations at facilities in Baltimore, Md. and Canton, Mass., resulting in a cutback of approximately 400 employees across the company.
Emergent expects the cuts to save an estimated $100 million a year. Due to the strategic shift away from the service business, it will be eliminating the chief operating officer position. As a result, current chief operating officer Adam Havey will exit the company on September 30, 2023.
“The actions we are taking will further strengthen our core products business and financial foundation,” said Haywood Miller, interim CEO, Emergent, in a company press release. “This will better align Emergent’s businesses with a focus on our core products and delivering for the needs of our customers. It will provide us with flexibility to respond to future customer demand while responsibly maintaining manufacturing infrastructure deemed critical to respond to public health threats.”
Reference: Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position. Emergent. August 8, 2023. Accessed August 9, 2023. https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-announces-strategic-steps-strengthen-core
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
